Daktacort (Miconazole/Hydrocortisone)
Is It Right for You?
A complete guide to Daktacort (Miconazole/Hydrocortisone) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Daktacort?
Daktacort is a dual-action topical cream that combines two active ingredients in a single formulation: miconazole nitrate 2% (a broad-spectrum imidazole antifungal) and hydrocortisone 1% (a mild topical corticosteroid). This combination allows simultaneous treatment of fungal skin infection and the accompanying inflammation that often makes such conditions itchy, painful, and slow to heal.
Daktacort is particularly suited to the initial inflammatory phase of conditions such as inflamed tinea pedis (athlete's foot), candidal intertrigo, sweat rash with secondary fungal overgrowth, and inflamed seborrhoeic or eczematous dermatoses where candidal infection is suspected or confirmed. Once the inflammation has settled — typically within several days — treatment is usually stepped down to plain miconazole cream to complete the antifungal course without continued corticosteroid exposure.
Daktacort is a prescription-only medication in the UK. (A lower-strength version, Daktacort HC, is available from a pharmacist for short-term use in adults under specific circumstances.) A licensed clinician must confirm the diagnosis, exclude viral infection, and assess the site and duration of treatment before prescribing.
What Conditions Is Daktacort Used For?
Daktacort is prescribed for inflammatory fungal skin conditions where both the inflammation and the infection require treatment:
Atopic eczema, contact dermatitis, discoid eczema, and seborrhoeic dermatitis complicated by superimposed candidal (yeast) infection. The combination of mild topical corticosteroid with antifungal cover addresses both the inflammatory and infective components simultaneously, which is particularly useful in moist or flexural sites where Candida overgrowth is common.
Inflammation of skin folds (under the breasts, in the groin, between the buttocks, abdominal folds) where heat, moisture, and friction predispose to candidal overgrowth. Daktacort's combined antifungal and anti-inflammatory action targets both the underlying yeast and the secondary inflammation that perpetuates the condition.
Athlete's foot complicated by significant inflammation, itching, and skin maceration. Miconazole provides the antifungal action against the dermatophyte, while hydrocortisone rapidly reduces the inflammation and pruritus that drive scratching and skin damage. Daktacort is typically used for the initial inflammatory phase, then stepped down to plain miconazole cream to complete the antifungal course.
Napkin rash complicated by Candida albicans — suggested by persistent bright red rash, satellite pustules extending beyond the main affected area, and incomplete response to barrier creams. Daktacort can be used short term under clinical supervision; the nappy area is prone to corticosteroid absorption so courses should be brief and applications sparing.
Sweat rash, particularly in warm climates or following heavy physical exertion, where occlusion and moisture have allowed superficial fungal and bacterial overgrowth on inflamed skin. Daktacort's combined action addresses both elements.
Daktacort should not be used for rosacea, acne, perioral dermatitis, or itchy skin without inflammation or infection. It is contraindicated in primary viral skin infections (cold sores, chickenpox, shingles, vaccinia) and is not appropriate for skin infections caused by Gram-negative bacteria. Inappropriate use on these conditions can worsen the underlying disease and cause significant adverse outcomes including skin atrophy and rebound flares.
How Does Daktacort Work?
Daktacort combines two active ingredients with complementary mechanisms that together target both the infective and inflammatory components of complicated fungal skin disease:
Miconazole nitrate (imidazole antifungal): Miconazole inhibits the fungal cytochrome P450 enzyme 14α-demethylase, blocking the synthesis of ergosterol — the essential structural sterol of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic precursors disrupt membrane integrity, increase permeability, and ultimately cause leakage of intracellular contents and fungal cell death. At higher concentrations, miconazole also interacts directly with fungal membrane lipids, producing additional fungicidal activity. It is active against the major dermatophytes (Trichophyton, Microsporum, Epidermophyton) and yeasts (particularly Candida albicans), and has useful activity against some Gram-positive bacteria including Staphylococcus aureus.
Hydrocortisone (mild topical corticosteroid): Hydrocortisone diffuses across keratinocyte and inflammatory cell membranes to bind intracellular glucocorticoid receptors. The receptor-ligand complex translocates to the nucleus and modulates gene transcription, suppressing the production of pro-inflammatory cytokines, reducing leukocyte recruitment, stabilising lysosomal membranes, and inhibiting phospholipase A2 — thereby reducing prostaglandin and leukotriene synthesis. The net effect is rapid relief of erythema, oedema, and pruritus. Hydrocortisone is classified as a mild (Group I, UK) topical corticosteroid, making it suitable for sensitive skin sites where more potent steroids would carry an unacceptable risk of atrophy.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Apply a thin layer of Daktacort to the affected area twice daily, usually morning and evening. Use the smallest amount needed to cover the affected skin; rub it in gently until absorbed.
Wash and dry your hands before and after application, unless the hands are the area being treated. Make sure the skin is clean and fully dry before applying.
Do not apply under occlusive dressings, plastic wrap, or tight clothing. Occlusion dramatically increases absorption of the corticosteroid component and raises the risk of skin atrophy and systemic effects.
Avoid use on the face, eyes, and broken or weeping skin. If accidental contact with the eyes occurs, rinse thoroughly with water.
Complete the recommended course. Once the inflammation has settled, your clinician may advise stepping down to plain miconazole 2% cream for a further 1–2 weeks to fully clear the fungal element without continued steroid exposure.
Do not exceed 7 days of continuous treatment without clinical review, particularly in children or when treating large areas of skin.
Side Effects of Daktacort
Most side effects are mild, local, and resolve on their own. Serious side effects are uncommon but require medical attention when they occur.
- Mild skin irritation, burning, or stinging on application
- Itching or dryness of the treated skin
- Mild redness
- Local contact dermatitis (uncommon)
- Skin atrophy (thinning), telangiectasia, and striae — risk increases with prolonged use, application to thin-skinned areas, and use under occlusion
- Hypothalamic-pituitary-adrenal axis suppression — rare; risk greatest with extensive application, occlusion, and in infants and children
- Severe hypersensitivity reactions — anaphylaxis to miconazole is rare; local allergic contact dermatitis with blistering and weeping may indicate hypersensitivity to one of the active ingredients or excipients
- Ocular adverse effects — if Daktacort enters the eyes, prolonged contact can contribute to glaucoma, cataracts, or blurred vision; rinse thoroughly if accidental exposure occurs
- Opportunistic infections — corticosteroid suppression of local immunity may allow new viral or resistant bacterial infections to develop
- Systemic miconazole effects — in patients on warfarin, even topical miconazole can significantly increase bleeding risk
Although Daktacort is applied topically, miconazole is absorbed in clinically significant amounts and can inhibit cytochrome P450 enzymes. The most important practical interaction is with warfarin: even short courses of topical Daktacort have been associated with significant rises in INR and serious bleeding. Patients on warfarin should be flagged before prescribing, and INR monitored more closely if Daktacort is used. Similar caution applies to sulfonylurea diabetes medications, where hypoglycaemia has been reported.
Drug Interactions
Although Daktacort is applied topically, small amounts of miconazole are absorbed systemically and can cause clinically significant interactions, particularly with warfarin and some oral diabetes medications. Always disclose all prescription medications, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting treatment.
Miconazole is absorbed in small amounts even from topical application and can inhibit cytochrome P450 enzymes (notably CYP2C9). This can significantly increase the anticoagulant effect of warfarin, raising INR and the risk of bleeding. Patients on warfarin who require Daktacort should be discussed with the prescribing clinician and INR monitored more frequently during treatment.
Concurrent use of other topical corticosteroids on the same or adjacent skin areas can compound the local and systemic adverse effects of corticosteroid therapy — including skin atrophy, telangiectasia, and (with extensive use) HPA-axis suppression. Avoid combining Daktacort with another topical steroid without explicit clinical advice.
Topical miconazole has been associated with raised plasma levels of orally administered sulfonylureas (such as gliclazide and glibenclamide), with reports of severe hypoglycaemia. Patients with diabetes on sulfonylureas should be monitored more closely for low blood sugar during Daktacort treatment, particularly with extensive or prolonged use.
Extensive or prolonged topical corticosteroid use, particularly under occlusion, can result in sufficient systemic absorption to cause mild immunosuppression — theoretically affecting the response to live attenuated vaccines (MMR, varicella, BCG, yellow fever). Clinical relevance is greatest in infants and children receiving treatment over large areas or under nappy occlusion. Disclose recent or planned live vaccinations to your clinician.
Important Warnings
Daktacort must not be applied to primary viral skin lesions including cold sores (herpes simplex), chickenpox, shingles, vaccinia, or molluscum contagiosum. The corticosteroid component suppresses local immune defences and can cause significant worsening or dissemination of viral infections.
Daktacort is not recommended for use on the face unless specifically directed by a clinician. Facial skin is thin and absorbs corticosteroids more readily, increasing the risk of skin atrophy, telangiectasia, perioral dermatitis, and rosacea-like eruptions.
Do not apply Daktacort under occlusive dressings such as waterproof bandages, plastic wrap, or tight nappies. Occlusion significantly increases corticosteroid absorption and the risk of skin thinning, striae, and systemic effects including adrenal suppression — a particular concern in infants and children.
Extended use of topical corticosteroids — particularly in children, on thin-skinned areas, or under occlusion — can cause permanent skin thinning, telangiectasia, striae, and systemic absorption sufficient to suppress the hypothalamic-pituitary-adrenal axis. Treatment courses should be as short as possible (typically no more than 7 days), and prolonged use requires direct clinical supervision.
Daktacort is not contraindicated in tuberculous skin affections, but should be used with particular caution and only under specialist advice in patients with active or suspected cutaneous tuberculosis, given that the corticosteroid component can suppress the host immune response to mycobacteria.
Safety in pregnancy and breastfeeding is not fully established. Use during pregnancy or while breastfeeding should be confined to circumstances where the clinical benefit clearly outweighs the theoretical risk, using the smallest amount for the shortest time. Avoid application to the nipple area in breastfeeding women.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Daktacort FAQs
Daktacort is generally not recommended for use on the face. Facial skin is thinner and absorbs corticosteroids more readily, which can lead to skin thinning, broken capillaries (telangiectasia), perioral dermatitis, and rosacea-like flares. If your clinician has specifically prescribed it for a facial condition, follow their instructions carefully and apply only the smallest amount for the shortest time.
Daktacort is intended for short-term use, typically a maximum of 7 days. If your skin condition has not improved by then, contact your clinician for review rather than continuing the cream. Once the inflammation has settled, your clinician may advise switching to plain miconazole 2% cream for a further 1–2 weeks to complete the antifungal treatment.
Daktacort combines two active ingredients — miconazole (antifungal) and hydrocortisone (mild corticosteroid) — designed to treat fungal skin infections that are also inflamed. Daktarin contains only miconazole. Daktacort is used first to settle the inflammation; once that has resolved, treatment is usually completed with Daktarin to clear the remaining fungal infection without continued steroid exposure.
You should not use Daktacort on broken or weeping skin, under tight dressings or nappies (which increase absorption), or on primary viral infections such as cold sores or chickenpox. Avoid the face, eyes, and inside the mouth or nose unless specifically directed by a clinician.
Yes — the miconazole component can interfere with warfarin and increase the risk of bleeding, even when used topically. It may also raise the effect of some sulfonylurea diabetes medications such as gliclazide. Always disclose all your prescription and over-the-counter medications to your clinician before starting Daktacort.
Daktacort is generally avoided in pregnancy and breastfeeding unless clearly necessary. Where treatment is essential, the smallest amount should be used for the shortest possible time. Breastfeeding women should avoid applying Daktacort to the nipple area to prevent infant exposure.
If you forget to apply Daktacort at the usual time, apply it as soon as you remember unless it is almost time for the next dose — in which case skip the missed dose and continue with your normal schedule. Do not apply extra to make up for the missed dose, as this does not improve results and increases the risk of side effects.